US 12219327
Substituted isoindolines as PI3K-alpha inhibitors
granted A61KA61K31/4035A61K31/404
Quick answer
US patent 12219327 (Substituted isoindolines as PI3K-alpha inhibitors) held by Relay Therapeutics, Inc. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Relay Therapeutics, Inc.
- Grant date
- Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/4035, A61K31/404, A61K31/4155, A61K31/416